Discovery Bioanalysis of Large Molecules
Discovery Bioanalysis of Large Molecules Services
To meet the broad needs for biologics discovery programs, Pharmaron has established a team specialized in various types of analytical technologies to analyze biologics, such as HPLC, LC/MS, Ligand-Binding Immunoaffinity (LBA) and PCR platforms. The team is highly experienced in developing new assays with various analytical platforms, with fast turnaround, to generate high-quality data to support discovery programs’ needs, for both in vitro and in vivo studies.
- Assay development, transferred and kit-based assay optimization to support discovery bioanalysis of therapeutic biologics
- Assay development, transferred and kit-based assay optimization for the analysis of ADA, ADCC, CDC and ADCP, TDAR and NAb, etc
- Assay development, assay transferred and kit-based assay optimization for analysis of biomarkers of interest, including DNA and mRNA based
Capabilities
Analytical Platforms
- HPLC
- LC/MS
- ELISA
- MSD
- HELISA
- FACS
- Luminex
- qPCR
- ddPCR
- Imaging-based methods: immunohistochemistry, liquid handling automation station
Analytes
- Recombinant proteins, peptides
- Antibodies, e.g. mAbs, ADCs, PDCs, Bis-Abs, nanobodies
- Vaccines
- Biomarkers: DNA, mRNA and small molecule-based biomarkers
- Fit for purpose method qualification/validation
- Methods adapted and validated for regulated preclinical/clinical studies
- Sample analysis for in vivo PK, PK/PD, TK assays, biomarker, immunogenicity, biodistribution studies
Learn more about Pharmaron’s large molecule bioanalytical services
